SCHEMBL14722729

SCHEMBL14722729

[N-]=[N+]=NCc1ccc2c(c1)ncn2C1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.38
TSHR P16473 1/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 2/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
YTHDC1 Q96MU7 1/20 0.34
ALDH1A1 P00352 5/20 0.33
HPGD P15428 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 2/20 0.33
TP53 P04637 1/20 0.33
CYP2C9 P11712 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1846614 0.81 CYP1A2 (0.42) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL1844662 0.81 HSD17B10 (0.42) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL14723488 0.78 NPC1 (0.43) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL15208540 0.75 RXRA (0.45) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL15209794 0.75 NPC1 (0.41) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL2144446 0.74 CYP2C19 (0.45) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL1846125 0.73 KMT2A (0.42) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL18309163 0.73 CYP2C19 (0.42) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL1844354 0.73 CYP1A2 (0.41) CYP1A2TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL1845611 0.73 CYP1A2 (0.41) CYP1A2TSHRNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 CYP1A2 4847/4885TSHR 1021/4885NPC1 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.